ClinicalTrials.gg
RecruitingNCT05223803Updated Jun 3, 2026

TERPS Trial for de Novo Oligometastic Prostate Cancer

A Phase 2 interventional study of Prostate radiation (XRT) and Systemic Therapy in Prostate Cancer and Oligometastatic Disease, sponsored by University of Maryland, Baltimore. Recruiting at 10 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore — 1 open to participants now, 4 under way, none of them phase 3. Prostatic Neoplasms · University of Maryland, Baltimore.

Planned enrollment
Largest of 10
122 · median 27
Started
2022
the only one that year
Phase 2
8 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore, this one has the largest planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 8 in phase 2, and was the 12th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.

Read the detailed description

This study will compare the effects, good and/or bad, of using the standard of care treatment (systemic therapy + primary prostate radiation) compared to standard of care treatment plus stereotactic ablative radiation therapy (SABR) to metastatic lesions for prostate patients. The researchers are also trying to learn if the addition of SABR will affect recurrence rates. Presence of circulating tumor cells, gut bacteria, and quality of life will be assessed for both groups.

03

Conditions studied

  • Prostate Cancer
  • Oligometastatic Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must have at least one and up to three asymptomatic tumor(s) of the bone or soft tissue (with at least one bone metastasis) develop within the past 6-months that are seen on imaging. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or PSMA PET-CT scan.

    1. CT or MRI scan within 6 months of enrollment
    2. Bone scan within 6 months of enrollment
    3. Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)
  2. Histologic confirmation of (primary or metastatic tumor).
  3. Patient may have had prior systemic therapy and/or ADT associated with treatment within 9-months of enrollment.
  4. PSA > 0.5 but \<100.
  5. Patient must be ≥ 18 years of age.
  6. Patient must have a ≥ 12 months.
  7. Patient must have an performance status ≤ 2.
  8. Patient must have the ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  1. Castration-resistant prostate cancer (CRPC).
  2. Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy
  3. Spinal cord compression or impending spinal cord compression.
  4. Suspected pulmonary and/or liver (greater >10 mm in largest axis).
  5. Patient receiving any other agents.
  6. Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist .
  7. Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.
  8. No radiographical evidence of cranial metastasis.
  9. Refusal to sign .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (estimated)

Study arms

  • Active comparator
    Best systemic therapy (BST) + primary prostate radiation (XRT)

    Radiation: Prostate radiation (XRT) · Drug: Systemic Therapy

  • Active comparator
    BST + XRT + SABR metastasis-directed therapy (MDT)

    Radiation: Prostate radiation (XRT) · Drug: Systemic Therapy · Radiation: Stereotactic ablative radiation therapy (SABR)

Interventions

  • RadiationProstate radiation (XRT)

    Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.

  • DrugSystemic Therapy

    All systemic therapy is provided as best prescribed for patient per their medical oncologist.

  • RadiationStereotactic ablative radiation therapy (SABR)

    SABR is delivered to those randomized to Arm 2.

06

What researchers measure

Primary outcomes

  1. To determine the 2-year failure-free survival (FFS) of men who have oligometastatic prostate cancer with BST+XRT versus BST+XRT+SABR MDT.

    Cross-over to the SABR MDT is allowed following failure.

    Time frame: 2 years

Secondary outcomes

  1. To determine the number of participants with toxicities related to SABR MDT in patients with de novo oligometastatic disease

    Adverse events will be assessed at baseline, on treatment visit, and follow-up visit.

    Time frame: 5 years

  2. To determine local control at 12-months after SABR MDT in patients with de novo oligometastatic disease.

    Time frame: 1 year

  3. To assess time to progression

    Progression will be assessed for time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival and duration of response after randomization to best systemic therapy (BST) and primary prostate radiation (XRT) versus BST, XRT and stereotactic ablative radiation therapy (SABR) metastasis-directed therapy (MDT).

    Time frame: 5 years

  4. Quality of life assessed through EPIC tool utilizing patient scores in each function group following completion of SABR MDT.

    EPIC quality of life tool will be used to assess quality of life following treatment. This survey will be completed at baseline and during follow-up visits. Averages will be taken for each section in the survey (Urinary Function, Bowel Function, Sexual Function, and Hormonal function).

    Time frame: 5 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jul 2028, 69 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 69 months is above that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Feb 4, 2022
StartActual
Oct 18, 2022
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2029
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05223803
Responsible party
Department of Radiation Oncology (Principal Investigator, University of Maryland, Baltimore) — Principal investigator
First posted
Feb 4, 2022
Start date
Oct 18, 2022
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Jun 3, 2026

Study contacts

Zaker Rana, MD
Contact
zaker.rana@umm.edu
410-369-5200
Nicole Helie
Contact
nicole.helie@umm.edu
410-328-6304

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion